Debate regarding oseltamivir use for seasonal and pandemic influenza

Emerging Infectious Diseases

Volumn 22, Issue 6, 2016, Pages 949-955

  Hurt, Aeron C ^a,b   Kelly, Heath ^c,d  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c PETER DOHERTY INSTITUTE FOR INFECTION AND IMMUNITY   (Australia)

^d AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

OSELTAMIVIR; PLACEBO; ZANAMIVIR; ANTIVIRUS AGENT;

ARTICLE; CLINICAL EFFECTIVENESS; COMMUNITY CARE; DEATH; EARLY INTERVENTION; GOVERNMENT; HUMAN; INFLUENZA A (H5N1); META ANALYSIS (TOPIC); PANDEMIC INFLUENZA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPEATED DRUG DOSE; SEASONAL INFLUENZA; SINGLE DRUG DOSE; VIRUS REPLICATION; CLASSIFICATION; CLINICAL TRIAL (TOPIC); DISEASE MANAGEMENT; GENETICS; INFLUENZA; INFLUENZA A VIRUS; PRACTICE GUIDELINE; SEASON; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VIROLOGY;

ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; DISEASE MANAGEMENT; HUMANS; INFLUENZA A VIRUS; INFLUENZA, HUMAN; OSELTAMIVIR; PRACTICE GUIDELINES AS TOPIC; SEASONS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84969131771     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid2206.151037     Document Type: Article

References (39)

1. Goldacre B. What the Tamiflu saga tells us about drug trials and big pharma. The Guardian. April 10, 2014.
2. Dobson J, Whitley RJ, Pocock S, Monto AS. Oseltamivir treatment for influenza in adults: A meta-analysis of randomised controlled trials. Lancet. 2015;385:1729-1737. http://dx.doi.org/10.1016/S0140-6736(14)62449-1
3. Jefferson T, Jones MA, Doshi P, Del Mar CB, Hama R, Thompson MJ, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev. 2014;4:CD008965.
4. Muthuri SG, Venkatesan S, Myles PR, Leonardi-Bee J, Al Khuwaitir TS, Al MA, et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: A meta-analysis of individual participant data. Lancet Respir Med. 2014;2:395-404. http://dx.doi.org/10.1016/S2213-2600(14)70041-4
5. Li KS, Guan Y, Wang J, Smith GJ, Xu KM, Duan L, et al. Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. Nature. 2004;430:209-213. http://dx.doi.org/10.1038/nature02746
6. Roche introduces program to facilitate corporate pandemic stockpiling of Tamiflu. PR Newswire, June 26, 2008 [cited 2015 Mar 30]. http://www.prnewswire.com/news-releases/roche-introduces-program-to-facilitate-corporate-pandemic-stockpiling-of-tamiflur-57551412.html
7. US Government Accounting Office. HHS spent nearly a quarter of the funds (about $1.30 billion) on activities related to developing and stockpiling antiviral drugs. GAO Report [cited 2015 Mar 30]. http://www.gao.gov/assets/330/320181.html
8. World Health Organization (WHO). Cumulative number of confirmed human cases for avian influenza A(H5N1) reported to WHO, 2003-2015 [cited 2015 Mar 30]. http://www.who.int/ influenza/human_animal_interface/EN_GIP_20150303cumulative NumberH5N1cases.pdf?ua=1.
9. Suda KJ, Hunkler RJ, Matusiak LM, Schumock GT. Influenza antiviral expenditures and outpatient prescriptions in the United States, 2003-2012. Pharmacotherapy. 2015;35:991-7. http://dx.doi.org/10.1002/phar.1656
10. Jefferson T, Jones M, Doshi P, Del MC, Dooley L, Foxlee R. Neuraminidase inhibitors for preventing and treating influenza in healthy adults. Cochrane Database Syst Rev. 2010;(2):CD001265.
11. Doshi P. Neuraminidase inhibitors—the story behind the Cochrane review. BMJ. 2009;339:b5164. http://dx.doi.org/10.1136/bmj.b5164
12. Jefferson T, Demicheli V, Rivetti D, Jones M, Di Pietrantonj C, Rivetti A. Antivirals for influenza in healthy adults: Systematic review. Lancet. 2006;367:303-313. http://dx.doi.org/10.1016/S0140-6736(06)67970-1
13. Kelly H, Cowling BJ. Influenza: The rational use of oseltamivir. Lancet. 2015;385:1700-1702. http://dx.doi.org/10.1016/S0140-6736(15)60074-5
14. Cressey D. Analysis of trial data revives flu-drug row. Nature. 2015 Jan 30 [cited 2016 Feb 2]. http://www.nature.com/news/ analysis-of-trial-data-revives-flu-drug-row-1.16820
15. Lee N, Choi KW, Chan PK, Hui DS, Lui GC, Wong BC, et al. Outcomes of adults hospitalised with severe influenza. Thorax. 2010;65:510-515. http://dx.doi.org/10.1136/thx.2009.130799
16. Hiba V, Chowers M, Levi-Vinograd I, Rubinovitch B, Leibovici L, Paul M. Benefit of early treatment with oseltamivir in hospitalized patients with documented 2009 influenza A (H1N1): retrospective cohort study. J Antimicrob Chemother. 2011;66:1150-5. http://dx.doi.org/10.1093/jac/dkr089
17. Kmietowicz Z. Study claiming Tamiflu saved lives was based on “flawed” analysis. BMJ. 2014;348:g2228. http://dx.doi.org/ 10.1136/bmj.g2228
18. Nguyen-Van-Tam JS. Principal author of PRIDE study responds to news story in the BMJ claiming that the study was based on “flawed” analysis. BMJ. 2014;348:g2935. http://dx.doi.org/10.1136/bmj.g2935
19. Antes G, Meerpohl JJ. Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality. Lancet Respir Med. 2014;2:e10. http://dx.doi.org/10.1016/S2213-2600(14)70127-4
20. Leonardi-Bee J, Venkatesan S, Muthuri SG, Nguyen-Van-Tam JS, Myles PR. Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality. Lancet Respir Med. 2014;2:e10-e12. http://dx.doi.org/10.1016/ S2213-2600(14)70137-7
21. Muthuri SG, Venkatesan S, Myles PR, Leonardi-Bee J, Lim WS, Mamun AA, et al. Impact of neuraminidase inhibitors on influenza A(H1N1)pdm09-related pneumonia: An IPD meta-analysis. Influenza Other Respi Viruses. 2015 Nov 25. Epub ahead of print. http://dx.doi.org/10.1111/irv.12363
22. Adisasmito W, Chan PK, Lee N, Oner AF, Gasimov V, Aghayev F, et al. Effectiveness of antiviral treatment in human influenza A(H5N1) infections: Analysis of a global patient registry. J Infect Dis. 2010;202:1154-1160. http://dx.doi.org/10.1086/656316
23. McGeer A, Green KA, Plevneshi A, Shigayeva A, Siddiqi N, Raboud J, et al. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis. 2007;45:1568-1575. http://dx.doi.org/10.1086/523584
24. Nordstrom BL, Zhu S, Smith JR. Reduction of influenza complications following oseltamivir use. Abstract 937. In: Proceedings and abstracts of the Second European Influenza Conference (St. Julian’s, Malta). St. Julian’s (Malta): European Scientific Working Group on Influenza; 2005.
25. Sprenger M, Pammer C. The evidence of oseltamivir (Tamiflu) in reducing influenza mortality; A response to ‘Experts question wisdom of stockpiling oseltamivir.’ BMJ. 2015;331. http://dx.doi.org/10.1136/bmj.331.7524.1041
26. Lee N, Chan PK, Rainer TH, Hui D, Choi KW, Cockram CS. Influenza virus load in hospitalised patients. Hong Kong Med J. 2013;19(Suppl 4):15-18.
27. de Jong MD, Simmons CP, Thanh TT, Hien VM, Smith GJ, Chau TN, et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med. 2006;12:1203-1207. http://dx.doi.org/10.1038/nm1477
28. Lee N, Wong CK, Chan PK, Chan MC, Wong RY, Lun SW, et al. Cytokine response patterns in severe pandemic 2009 H1N1 and seasonal influenza among hospitalized adults. PLoS ONE. 2011;6:e26050. http://dx.doi.org/10.1371/journal.pone.0026050
29. To KK, Hung IF, Li IW, Lee KL, Koo CK, Yan WW, et al. Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection. Clin Infect Dis. 2010;50:850-9. http://dx.doi.org/10.1086/650581
30. Hayden FG, Treanor JJ, Fritz RS, Lobo M, Betts RF, Miller M, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA. 1999;282:1240-6. http://dx.doi.org/10.1001/jama.282.13.1240
31. Oh DY, Barr IG, Hurt AC. A novel video tracking method to evaluate the effect of influenza infection and antiviral treatment on ferret activity. PLoS ONE. 2015;10:e0118780. http://dx.doi.org/ 10.1371/journal.pone.0118780
32. Kumar A. Early versus late oseltamivir treatment in severely ill patients with 2009 pandemic influenza A (H1N1): speed is life. J Antimicrob Chemother. 2011;66:959-963. http://dx.doi.org/ 10.1093/jac/dkr090
33. Sugaya N, Shinjoh M, Mitamura K, Takahashi T. Very low pandemic influenza A (H1N1) 2009 mortality associated with early neuraminidase inhibitor treatment in Japan: analysis of 1000 hospitalized children. J Infect. 2011;63:288-94. http://dx.doi.org/10.1016/j.jinf.2011.06.008
34. Burioni R, Canducci F, Clementi M. Pregnancy and H1N1 infection. Lancet. 2009;374:1417-1418. http://dx.doi.org/10.1016/S0140-6736(09)61853-5
35. Nakai A, Saito S, Unno N, Kubo T, Minakami H. Review of the pandemic (H1N1) 2009 among pregnant Japanese women. J Obstet Gynaecol Res. 2012;38:757-62. http://dx.doi.org/10.1111/j.1447-0756.2011.01812.x
36. Gutiérrez-Mendoza LM, Schwartz B, Mendez de Lira JJ, Wirtz VJ. Oseltamivir storage, distribution and dispensing following the 2009 H1N1 influenza outbreak in Mexico. Bull World Health Organ. 2012;90:782-7. http://dx.doi.org/10.2471/BLT.11.101733
37. The Academy of Medical Sciences/Wellcome Trust. Use of neuraminidase inhibitors in influenza [cited 2015 Dec 15]. http://www.wellcome.ac.uk/stellent/groups/corporatesite/@policy_ communications/documents/web_document/wtp059874.pdf.
38. South East Asia Infectious Disease Clinical Research Network. Effect of double dose oseltamivir on clinical and virological outcomes in children and adults admitted to hospital with severe influenza: double blind randomised controlled trial. BMJ. 2013;346:f3039. http://dx.doi.org/10.1136/bmj.f3039
39. Nguyen-Van-Tam JS, Venkatesan S, Muthuri SG, Myles PR. Neuraminidase inhibitors: Who, when, where? Clin Microbiol Infect. 2015;21:222-5. http://dx.doi.org/10.1016/j.cmi.2014.11.020